Non-typeable Haemophilus influenzae (NTHi) is an opportunistic pathogen that plays a major role in a number of respiratory tract infections, including otitis media, cystic fibrosis and chronic obstructive pulmonary disease. Biofilm formation has been implicated in both NTHi colonization and disease, and is responsible for the increased tolerance of this pathogen towards antibiotic treatment. Targeting metabolic pathways that are important in NTHi biofilm formation represents a potential strategy to combat this antibiotic recalcitrance. A previous investigation demonstrated increased expression of a putative D-methionine uptake protein following exposure of NTHi biofilms to the ubiquitous signalling molecule, nitric oxide. We therefore hypothesized that treatment with exogenous D-methionine would impact on NTHi biofilm formation and increase antibiotic sensitivity. Treatment of NTHi during the process of biofilm formation resulted in a reduction in biofilm viability, increased biomass, changes in the overall biofilm architecture and the adoption of an amorphous cellular morphology. Quantitative proteomic analyses identified 124 proteins that were differentially expressed following D-methionine treatment, of which 51 (41 %) were involved in metabolic and transport processes. Nine proteins involved in peptidoglycan synthesis and cell division showed significantly increased expression. Furthermore, D-methionine treatment augmented the efficacy of azithromycin treatment and highlighted the potential of D-methionine as an adjunctive therapeutic approach for NTHi biofilm-associated infections.
INTRODUCTION
Non-typeable Haemophilus influenzae (NTHi) is a Gramnegative coccobacillus that asymptomatically colonizes the human nasopharynx, and is also a significant opportunistic pathogen in a variety of human respiratory tract diseases, including chronic obstructive pulmonary disease, cystic fibrosis and otitis media [1] [2] [3] . The persistence and recurrence of NTHi infection despite antibiotic treatment is an important problem in clinical settings, and is likely associated with intracellular invasion of airway epithelial cells and biofilm formation [4, 5] . Biofilms are aggregated bacterial cells surrounded by a self-produced extracellular polymeric substance (EPS) comprising extracellular DNA, polysaccharides and protein.
The EPS matrix, which provides a physical barrier to attenuate the ingress of antimicrobials, and dormant bacterial populations within the biofilm both contribute to the increased antibiotic tolerance associated with biofilms [6, 7] . The close proximity of bacteria within the biofilm can also facilitate genetic exchange and lead to the development of antibacterial resistance. New therapeutic strategies that target NTHi biofilms effectively and reduce the risk of antibiotic tolerance and resistance are therefore needed.
One strategy to combat biofilm-associated infections uses metabolic triggers such as carbohydrates or amino acids, which may stimulate a metabolically active and replicative state, thereby rendering bacteria within biofilms sensitive to antibiotic treatment. Alternatively, these substrates may serve as signals that trigger endogenous pathways to break down established biofilms. The utilization of amino acids in particular has garnered considerable interest. For example, the introduction of exogenous L-arginine has been shown to impact on the regulation of biofilms formed by oral streptococci [8] [9] [10] . At high concentrations (>5 mM), L-arginine reduced biomass and altered the architecture of single-species biofilms formed by Streptococcus gordonii [8] . In addition, Larginine has also proven to be successful in the treatment of multi species oral biofilms formed by S. gordonii, Streptococcus mutans and Actinomyces naeslundii on hydroxyapatite discs coated with human whole saliva to mimic cariogenic conditions [9] . In this model the addition of L-arginine repressed genes involved in the production of EPS (gftB) and bacteriocin (SMU.150) in S. mutans, and increased the expression of spxB (involved in hydrogen peroxide production) in S. gordonii. These effects resulted in the suppression of S. mutans outgrowth and significant changes in EPS. Treatment with high concentrations of L-arginine (500 mM) also altered the species composition of polymicrobial oral biofilms formed in saliva, reduced overall biovolume and increased the efficacy of the antimicrobial agent cetylpyridinium chloride when administered together [10] .
Another amino acid, L-methionine (0.5 µM), has shown efficacy in both the inhibition of biofilm formation and the disassembly of established Pseudomonas aeruginosa biofilms [11] . These responses were specific to the L-isomeric form and were associated with up-regulation of four DNase genes (sbcB, endA, eddB, recJ), resulting in the degradation of eDNA in the EPS matrix and the inhibition of P. aeruginosa swarming and twitching motility. Furthermore, the intranasal administration of L-methionine as an adjuvant with ciprofloxacin for the treatment of murine chronic P. aeruginosa lung infection resulted in both increased sensitivity to antibiotic treatment and enhanced survival of treated mice [11] . No adverse effects towards D or DL methionine have been reported in adults or children, with a single dose of 100 mg kg À1 body weight considered to be safe; however, there is evidence that if it is administered in excess, a resultant increase in homocysteine can result in vascular damage and cardiovascular disease [12] .
We previously reported that treatment with the ubiquitous signalling molecule, nitric oxide (NO), correlated with the increased expression of a putative D-methionine-binding lipoprotein (MetQ) in NTHi biofilms [13] . The increased expression of this protein, in addition to other proteins involved in metabolic or transcriptional/translational processes, enhanced the antibiotic sensitivity of NTHi biofilms formed on ciliated primary respiratory epithelial cells [13] . We therefore hypothesized that treatment of established NTHi biofilms with exogenous D-methionine would impact upon NTHi biofilm development and potentially reduce biofilm-associated antibiotic tolerance. Quantitative proteomic analyses were performed to characterize any responsive protein adaptations to the presence of exogenous D-methionine in NTHi biofilms.
METHODS

Bacterial strain and growth conditions
In vitro biofilm experiments were performed using a clinical NTHi strain isolated from sputum of a primary ciliary dyskinesia patient (obtained under Southampton and South West Hampshire Research Ethics approval 07/Q1702/109). The strain was subcultured onto Colombia agar with chocolated horse blood (CBA; Oxoid, UK) from a frozen stock and incubated for 18 h at 37 C/5 % CO 2 . Colonies were resuspended in brain heart infusion (BHI) broth supplemented with 10 µg ml À1 haemin and 2 µg ml À1 nicotinamide adenine dinucleotide, and incubated at 37 C/5 % CO 2 . Mid-exponential planktonic cultures were then used to inoculate untreated polystyrene six-well plates with approximately 1Â10 8 cells, with additional supplemented BHI introduced to support growth. Biofilms were grown for 24 h at 37 C/5 % CO 2 .
Biofilm treatment and assessment of viability
To evaluate the effect of exogenous D-and L-methionine on viability, biofilms were grown in the presence of 100 µM-20 mM of each enantiomer (prepared in supplemented BHI) for 24 h at 37 C/5 % CO 2 . After 24 h, the treatments were removed and the biofilms were rinsed twice in Hanks' Balanced Salt Solution (HBSS) to remove residual treatment and unattached cells. To assess antibiotic activity, the biofilms were subsequently treated with azithromycin (1 mg ml À1 ) for 2 h and then rinsed twice with HBSS. The biofilms were resuspended in HBSS through scraping and vortexing, serial diluted in HBSS and then spot-plated onto CBA plates. The plates were incubated for 18 h at 37 C/5 % CO 2 and then viability was assessed through enumeration of the colony-forming units (c.f.u.). Confocal laser scanning microscopy (CLSM) was performed as previously described, using a Leica SP8 confocal laser scanning microscope with a 63Â oil immersion lens and the LIVE/DEAD BacLight bacterial viability kit (Life Technologies, USA) [14] . The maximum biofilm thickness and the number of individual live cells in confocal z-stacks were determined using COMSTAT 2.1 and ImageJ software [15] .
Scanning electron microscopy
NTHi biofilms were grown in the presence of 20 mM D-or L-methionine for 24 h as described above, but ethanol-sterilized 13 mm glass coverslips were inserted into each well. The biofilms were processed as previously described [16] , and imaged using a Quanta 250 scanning electron microscope (FEI, USA).
Transmission electron microscopy
NTHi biofilms were grown in the presence of 20 mM D-or L-methionine for 24 h as described above, rinsed twice with HBSS and then fixed in 3 % glutaraldehyde (TAAB, UK) in 0.1 M cacodylate buffer (Agar Scientific, UK). The cells were then spun down into 5 % aqueous sodium alginate (Thermo Fisher Scientific, UK) at 4500 g. The supernatant was mixed with an equal volume of 0.1 M calcium chloride (Thermo Fisher Scientific) to set the alginate. The alginate cell pellet was rinsed in 0.1 M cacodylate buffer and postfixed in 2 % osmium tetroxide (Oxkem, UK) in 0.1 M cacodylate buffer. Samples were rinsed briefly in distilled water, block stained in 2 % aqueous uranyl acetate (Agar Scientific, UK) for 30 min, rinsed briefly in distilled water and dehydrated through a graded ethanol series (70-100 %) (Thermo Fisher Scientific), and then embedded in Spurr replacement resin (Agar Scientific, UK). Gold/silver sections were cut using a Leica Ultra-cut E ultramicrotome. The sections were stained with Reynolds lead stain and viewed on a Hitachi H7000 transmission electron microscope equipped with an SIS Megaview III digital camera.
Sample preparation for proteomic analysis
All chemicals were purchased from Sigma-Aldrich (Gillingham, UK) unless noted otherwise. NTHi biofilms were grown in the presence of 20 mM D-methionine for 24 h as described above. Biofilms were rinsed twice with 0.1 M triethylammonium bicarbonate (TEAB) buffer and then resuspended in 0.1 M TEAB by vortexing and scraping. Samples were lysed in lysing matrix B (MP Bioscience, UK) using a TissueLyser LT (Qiagen, UK) in six 30 s sessions with 30 s storage on ice between sessions. The lysates were centrifuged at 855 g/5 min, and the supernatant was retained, with sodium dodecyl sulphate (SDS) being added to a final concentration of 2 % v/v. Samples were shaken on ice for 1 h and then subjected to protein determination using the Pierce BCA protein assay (Thermo Fisher Scientific). A total of 50 µg of total protein from each sample was reduced by the addition of DL-Dithiothreitol (DTT, final concentration 100 mM), followed by trypsin digestion using the filteraided sample preparation (FASP) method modified from [17] . For this, samples were diluted four times with 8 M urea (GE Healthcare Life Sciences, UK), applied on Nanosep 30k Omega filters (Pall Life Sciences, UK), and washed repeatedly with 8 M urea to remove SDS. Alkylation was performed with methyl methane thiosulfonate (MMTS, final concentration 10 mM) diluted in digestion buffer [1 % sodium deoxycholate (SDC), 50 mM TEAB] and the filters were repeatedly washed with digestion buffer afterwards. Protein digestion using an enzyme : protein ratio of 1 : 100 was performed by two sequential incubations with trypsin (Pierce Trypsin Protease, MS Grade, Thermo Fisher Scientific) at 37 C (first iteration overnight, second for 4 h) in digestion buffer. The resulting tryptic peptides were collected by centrifugation, and each sample was labelled with the isobaric mass-tagging reagent TMT 10plex according to the manufacturer's instructions (Thermo Fisher Scientific). After differential labelling, the peptides from all the samples were combined and acidified to pH2 to enable the precipitation of SDC by centrifugation. Afterwards, peptides were fractionated using the Pierce high-pH reversed-phase peptide fractionation Kit (Thermo Fisher Scientific). Eight fractions with increasing concentrations of acetonitrile were collected according to the manufacturer's protocol, and dried by Speedvac. For LC-MS/MS analysis, the samples were resolved in 20 µl of 3 % acetonitrile, with 0.1 % formic acid, the potential debris was pelleted by centrifugation and the supernatants were transferred into TopSert TPX snap ring vials (Genetec, Canada).
LC-MS/MS analysis
Each of the eight TMT-labelled fractions was analysed on an Orbitrap Fusion Tribrid mass spectrometer coupled to an Easy nanoLC1000 (Thermo Fisher Scientific). The peptides (3 µl injection volume) were separated using an analytical column (250Â0.075 mm i.d.), NanoViper Acclaim Pepmap C18 (particle size, 3 µm) with a pre column NanoViper C18 (particle size, 5 µm; 20Â0.0100 mm i.d.) (Thermo Fisher Scientific). Solvent A was 0.2 % formic acid in water and solvent B was 0.2 % formic acid in acetonitrile. The following gradient was run at 300 nl min À1 : 5-25 % B over 45 min, 25-80 % B over 5 min and a final hold at 80 % B for 10 min. Ions were injected into the mass spectrometer under a spray voltage of 2.0 kV in positive ion mode. MS scans were performed at a resolution of 120 000, m/z range 380-1200, and MS/MS analysis was performed in a data-dependent multi-notch mode, with a top speed cycle of 3s for the most intense doubly or multiply charged precursor ions. The ions in each MS scan over threshold 10 000 were selected for fragmentation (MS2) by collision-induced dissociation (CID) for identification at 30 % and detection in the ion trap, and this was followed by multi-notch (simultaneous) isolation of the top five MS2 fragment ions, with m/z 400-900, which were selected for fragmentation (MS3) by high-energy collision dissociation (HCD) at 55 % and detection in the Orbitrap at a resolution of 60 000, m/z range 100-500. Precursors were isolated in the quadrupole with a 1.6 m/z window, and dynamic exclusion within 20 ppm during 30 s was used for the m/z values already selected for fragmentation.
Database search and TMT quantification of proteins
MS raw data files for the TMT set were merged for relative quantification and identification using Proteome Discoverer version 1.4 (Thermo Fisher Scientific). A database search for each set was performed with the Mascot search engine (Matrix Science, USA) using the Haemophilus influenzae (strain 86-028 NP) UniProt database, version February 2016. MS peptide accuracy of 5 ppm and MS/MS tolerance were set for the identification of 500 millimass units (mmu), tryptic peptides with zero missed cleavages and methionine oxidation were set as variable modifications, while cysteine alkylation, the N-terminal TMT label and the lysine TMT label were selected as fixed modifications. The detected peptide threshold in the software was set to a significance of false discovery rate 1 % by searching against a reversed database, and the identified proteins were grouped by sharing the same sequences to minimize redundancy. For TMT quantification, the ratios of the TMT reporter ion intensities in the HCD MS/MS spectra (m/z 126-131) from raw data sets were used. The ratios were derived by Proteome Discoverer using the following criteria: the fragment ion tolerance was 3 mmu for the centroid peak with the smallest delta mass and a minimum intensity of 2000. Only peptides unique for a given protein were considered for relative quantitation, excluding those common to other isoforms or proteins of the same family. The quantification was normalized using the protein median. Inclusion criteria for quantitative analysis were set at !2 peptide matches, !50 protein score and !5 % sequence coverage (P<0.05). Comparative protein data with >1.3 and <0.77 ratios were classed as being differentially expressed. Proteins were analysed using the STRING functional protein association networks database (version 10.0) and the Gene Ontology (GO) database (version 1.2, released 27 October 2016) with the Protein ANalysis THrough Evolutionary Relationships (PANTHER) tool.
Statistical analysis
Statistical analysis of c.f.u. data was performed using Prism 6 (GraphPad, USA), with one-way analysis of variance (ANOVA) and nonparametric Kruskal-Wallis testing. P values <0.05 were considered statistically different.
RESULTS
NTHi biofilms grown in the presence of exogenous D-methionine demonstrated reduced viability
We previously reported the increased expression of a Dmethionine uptake lipoprotein in NTHi biofilms following treatment with exogenous NO, which suggested a possible role for D-methionine in an amino acid adaptive response. We therefore hypothesized that the presence of exogenous D-methionine may impact on NTHi biofilm development. We found that the viability of NTHi biofilms grown for 24 h in the presence of 100 µM-15 mM D-methionine was unaffected. However, a log-fold reduction was observed at a concentration of 20 mM of exogenous D-methionine (P<0.01; Fig. 1a ). To determine whether this response was specific to the D-enantiomer, we also assessed the effect of equimolar concentrations of L-methionine on biofilm formation and observed no effect on viability ( Fig. 1a ). We also examined whether this response was biofilm-specific by assessing the effect of D-methionine on planktonic NTHi populations. Treatment with 100 µM-10 mM D-methionine had no effect on planktonic growth over 7 h, but a notable reduction in growth was observed from treatment with 15 or 20 mM Dmethionine ( Fig. 1b) , which suggests that the resultant reduction in biofilm viability could potentially be attributed to slow-growing planktonic cells. In comparison, treatment with 20 mM L-methionine had no effect on planktonic growth (Fig. 1c ).
D-methionine impacts upon NTHi biofilm architecture and cellular morphology
In order to assess the effect of 20 mM D-methionine on biofilm architecture, we performed scanning electron microscopy (SEM). SEM imaging revealed that whilst Lmethionine had no obvious effect on biofilm architecture, the presence of D-methionine resulted in the compact aggregation of cells and evidence of abnormal cellular morphology ( Fig. 2a-c) . To further investigate this change in cellular structure, we performed transmission electron microscopy (TEM). TEM demonstrated that D-methionine had caused the majority of bacteria to adopt an irregular cell morphology and increase in size, with a number of cells reaching~4 µm in diameter, compared to a typical size of 1Â0.3 µm in untreated biofilms ( Fig. 2d-i ).
D-methionine changed the protein expression profile of NTHi biofilms
We performed quantitative proteomic analyses to further shed light on the possible mechanisms by which D-methionine affects NTHi biofilm formation and cellular morphology. Quantitative analyses comparing untreated 24 h NTHi biofilms to those grown in the presence of 20 mM D-methionine identified a total of 960 individual proteins shared between both populations. A total of 124 (13 %) were differentially expressed in the presence of 20 mM D-methionine and involved in a range of biological functions (Fig. 3) . Seventy-three (60 %) of these proteins showed decreased expression and a significant proportion was associated with metabolic (18 proteins) or transport (15 proteins) processes ( Table 1 ). Fifty-one (40 %) proteins showed increased expression, with metabolic and transport processes (nine proteins each) again being well represented. In addition, eight proteins involved in transcriptional and translational processes were increased in expression, as were nine proteins involved in cell wall formation, peptidoglycan synthesis and cell division (Table 1) . Notably, D-methionine also resulted in the increased expression of two stress-response proteins, GrpE (1.54-fold) and SpoT (1.31-fold), during biofilm formation. The expression of proteins involved in nitrogen metabolism and cellular iron ion homeostasis was also reduced in NTHi biofilms exposed to D-methionine. Specifically, there was a decrease in the expression of NrfA, NrfB and NrfCwhich belong to the single H. influenzae nitrite reductase encoded by the nrfABCD operon and are involved in nitrite reductionas well as NapA, which is also involved in nitrate reduction (Table 1) .
Exogenous D-methionine interfered with peptidoglycan synthesis during NTHi biofilm formation
The most striking changes observed with exogenous Dmethionine involved the cellular morphology within NTHi biofilms and the increase in the expression of proteins associated with cell wall formation, peptidoglycan synthesis and cell division. In total, 31 proteins (25 %) were quantitatively identified, of which 9 were increased in expression and only 1 (MurB) showed decreased expression ( Fig. 4a ). Seven of these differentially expressed proteins (MurB, MurC, MurD, MurE, MurF, Ddl and MraY) are involved in peptidoglycan synthesis, while FtsA and FtsL are involved in cell division, and MraZ is involved in the transcriptional regulation of cell division and peptidoglycan synthesis genes. Notably, the 9 proteins that showed increased expression are encoded by genes belonging to the dcw cluster, which comprises 15 IP: 54.70.40.11
On: Mon, 07 Jan 2019 05:51:47 genes involved in peptidoglycan synthesis and cell division [18] [19] [20] (Fig. 4b) . MurB, the only protein that decreased in expression, is encoded by a gene outside the dcw cluster. D-methionine increased biofilm biomass and sensitivity towards treatment with azithromycin Finally, we tested whether the architectural or cellular changes induced by D-methionine during NTHi biofilm formation impact on biofilm antibiotic tolerance. Treatment of 24 h NTHi biofilms established in the absence of D-methionine with 1 mg ml À1 azithromycin for 2 h, and growth in the presence of 20 mM D-methionine for 24 h without antibiotic treatment, both resulted in a log-fold reduction in the number of viable cells within the biofilm (P<0.05; Fig. 5b ). In contrast, biofilms grown in the presence of D-methionine for 24 h and then subsequently treated with 1 mg ml À1 azithromycin for 2 h showed a significant 2-log reduction in biofilm viability (P<0.05; Fig. 5b ). CLSM imaging revealed that D-methionine caused an increase in biofilm biomass over 24 h, with biofilms reaching a maximum height of 41 µm, compared with~23 µm for untreated biofilms (Fig. 5a, c) . COMSTAT and ImageJ analyses also indicated that the untreated and D-methionine-treated biofilms contained 8.3Â10 4 and 9.6Â10 4 individual live cells in their z-stacks, respectively (Fig. 5d ). Treatment with 1 mg ml À1 azithromycin had no effect on maximum biofilm thickness, but reduced the number of live cells to 5.9Â10 4 , whereas combined treatment with 20 mM D-methionine increased the maximum biofilm thickness to~37 µm and reduced the number of live cells to 5.5Â10 4 (Fig. 5c, d ).
DISCUSSION
Targeting pathways that are differentially expressed during biofilm development in response to specific signals offers a potential strategy to address elevated antibiotic tolerance in bacterial biofilms. We previously investigated the role of NO and its use as an adjuvant therapy to antibiotic treatment in NTHi biofilms. This work indicated that increased sensitivity to azithromycin treatment was associated with NO-mediated modulation of metabolic activity [13] . The increased expression of the putative D-methionine-binding lipoprotein (MetQ) following exposure to NO, in particular, represented a promising target that warranted further investigation. We hypothesized that exogenous D-methionine might influence NTHi biofilm development and increase susceptibility to antibiotic treatment. Our findings show that the introduction of 20 mM D-methionine during NTHi biofilm development resulted in both reduced viability and an increase in biomass, and that equimolar concentrations of the L-enantiomer failed to elicit the same response. Visually, confocal imaging appeared to suggest an increase in the number of live cells within D-methionine-treated biofilms; however, image analyses revealed that the live population was similar to that of the untreated biofilms. This disparity can be explained, in part, by the change in NTHi morphology as a result of D-methionine treatment, with the cells appearing to be densely aggregated, amorphous and significantly larger in size compared to those in untreated biofilms. This does not, however, account for the reduction in viability observed through c.f.u. enumeration. Although the number of live-stained cells present within the biofilm is similar between untreated and D-methionine-treated biofilms, the reduction in c.f.u. could perhaps be attributed to impaired NTHi fitness and growth, resulting in a 'viable but non-culturable' state. This is supported by a D-methionine-mediated reduction in planktonic growth, a response that was not observed from treatment with equimolar L-methionine.
Quantitative proteomic analyses were performed to elucidate the underlying mechanisms responsible for the change in biofilm architecture and cellular structure. Of the 960 individual proteins identified and quantified, only 124 (13 %) were found to be differentially expressed in response to D-methionine.
Unsurprisingly, a significant proportion of these were involved in metabolic (27 proteins) , transport (24 proteins) or transcriptional/translational (10 proteins) processes, which are commonly associated with biofilm formation and the response to external factors. Whilst these proteins undoubtedly play an important role in biofilm adaptive responses, we hypothesized that other identified proteins provided a more mechanistic insight into the response to D-methionine. Notably, two stress-related proteins were increased in expression: GrpE, which is involved in the response to hyperosmotic stress and heat shock and prevents stress-denatured protein aggregation [21] , and SpoT, which has been shown to mediate the stringent response in bacteria, as well as biofilm formation through regulation of the secondary messenger (p)ppGpp [22, 23] . We also found that proteins involved in nitrite (NrfA, NrfB and NrfC) and nitrate (NapA) reduction, which play important roles in protecting NTHi from host NO, showed significantly decreased expression. Deletion of nrfA has been shown to increase NTHi sensitivity towards NO [24] . These observations suggest that adjunctive treatment involving Dmethionine and NO-donor compounds might represent a potential treatment strategy for NTHi biofilm-associated infections.
It is the changes in the expression of the proteins involved in peptidoglycan synthesis, cell wall formation and cell division that are most intriguing, in light of the abnormal cellular morphology of the NTHi inhabiting the biofilm. Dmethionine induces the expression of proteins that are encoded by genes in the dcw operon, leading to the dysregulation of peptidoglycan synthesis and the enlarged, amorphous morphology of the cells. Confocal imaging also revealed that D-methionine increased biofilm formation, a response that is in concordance with previous work that demonstrates a link between interference with peptidoglycan synthesis and increased NTHi biofilm formation [25] .
In that study, transposon mutants in specific peptidoglycan synthesis genes (ponA, ampG, amiB and mrdA) demonstrated increased biofilm formation as a result of bacterial lysis and the release of extracellular DNA. D-methionine has also previously been shown to elicit changes in the macromolecular peptidoglycan of Escherichia coli, with its incorporation resulting in a significant change in the proportion of all muropeptide groups, the accumulation of two major modified muropeptides and a significant reduction in crosslinked muropeptides [26] . While it is possible that a similar mechanism could be involved in NTHi, no effect on E. coli cellular morphology was observed in that particular study. It was, however, suggested that D-methionine might also have a direct inhibitory effect on penicillin-binding proteins and biosynthetic enzymes. D-methionine is also incorporated into the cell wall muropeptides of other bacterial species, replacing D-Ala in the fourth and fifth positions [27] . Incorporation into the fifth position in Vibrio cholerae was shown to be dependent on D-methionine utilization by Ddl and MurF, which both showed increased expression in our study, suggesting that D-methionine is an alternative substrate for these enzymes [27] .
Finally, we also demonstrated that D-methionine has the potential to increase the sensitivity of NTHi towards macrolide antibiotics through this interference in peptidoglycan synthesis, highlighting its potential role as an adjuvant treatment agent.
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